Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 85 for your search:
Drug:
incomplete Freund's adjuvant
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III Randomized Study of Sargramostim (GM-CSF) and Peptide Vaccination Comprising Tyrosinase:368-376, gp100:209-217 (210M) Antigen, and MART-1:27-35 Peptide Versus Peptide Vaccination Alone Versus GM-CSF Alone Versus Placebo in Patients With Locally Advanced or Metastatic Melanoma
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ECOG-4697
, SWOG-E4697, E4697, NCT00005034
2.
Phase I/II Pilot Study of p53 Vaccine in Patients With Adenocarcinoma of the Ovary Who Have No Evidence of Disease or Marker Disease Only
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-99-C-0137
, NCI-NMOB-9903, NCI-T99-0074, T99-0074, NCT00019903
3.
Phase I/II Randomized Study of PR1 Leukemia Peptide Vaccine and Montanide ISA-51 in Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndromes
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
Over 18
Sponsor:
NCI
Protocol IDs:
MDA-DM-97325
, NCI-T98-0017, NCT00004918, T98-0017
4.
Phase I/II Study of Human Alpha Fetoprotein Peptide Immunization in HLA-A*0201 Positive Patients With Hepatocellular Carcinoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
Over 18
Sponsor:
NCI
Protocol IDs:
UCLA-9905003
, NCI-H00-0053, NCT00005629
5.
Phase I/II Study of Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes After Cyclophosphamide and Fludarabine in Patients With Metastatic Melanoma (Phase I Closed to Accrual as of 3/29/06)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-03-C-0162
, NCI-5855, 5855, NCT00062036
6.
Phase I/II Randomized Study of Vaccine Comprising Multiple Synthetic Melanoma Peptides, Montanide ISA-51, and Sargramostim (GM-CSF) in Patients With Stage IIIB, IIIC, or IV Melanoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UVACC-MEL-41
, UVACC-28502, UVACC-HIC-10464, NCT00089219
7.
Phase I/II Study of Adjuvant Vaccine Therapy Comprising Either Epstein-Barr Virus-Encoded Latent Membrane Protein (LMP)-2: 340-349 Peptide or LMP-2: 419-427 Peptide Emulsified in Montanide ISA-51 or Observation Alone in Patients With Anaplastic Nasopharyngeal Carcinoma at High Risk for Recurrence
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
Over 18
Sponsor:
NCI
Protocol IDs:
NCI-04-CC-0118
, NCT00112541
8.
Phase I/II Randomized Study of Adjuvant Vaccine Therapy Comprising Multi-Epitope Melanoma Peptides in Combination With Either Multi-Epitope Melanoma Helper Peptides or Tetanus Toxoid Helper Peptide Emulsified in Montanide ISA-51 With Versus Without Cyclophosphamide in Patients With Resected Stage IIB-IV Melanoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UVACC-HIC-11491
, Mel 44, UVACC-34104, UVACC-MEL-44, UVACC-GCRC-CLS013, UVACC-HITC-02620, MDA-2005-0070, NCT00118274
9.
Immunization With 8 Peptides Mixed With Adjuvant Montanide ISA 51 in HLA-A2 Patients With Metastatic Cutaneous Melanoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Temporarily closed
Age:
18 and over
Sponsor:
Other
Protocol IDs:
LUD2003-007
, NCT00145158
10.
Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
20 to 80
Sponsor:
Other
Protocol IDs:
FPCR1R2-2
, NCT00655785
11.
Phase II Pilot Study of HER2-Neu Peptide Vaccine in Patients with Recurrent Metastatic Cancer
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-97-C-0118
, NCI-T97-0009, T97-0009
12.
Phase II Study of Immunization with Immunodominant Tyrosinase and gp100 Peptides in Patients With Recurrent or Refractory Metastatic Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
NCI-98-C-0022
, NCI-T97-0088, T97-0088, NCT00019383
13.
Phase II Study of Immunization Comprising Immunodominant Peptides from 3 Melanoma Antigens (MART-1, gp100, and Tyrosinase) in Patients With Refractory Metastatic Melanoma (Summary Last Modified 10/2000)
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
NCI-98-C-0023
, NCI-T97-0089, T97-0089
14.
Phase II Study of Flt3 Ligand Alone or in Combination With Melanoma Peptide Immunization in Patients With Metastatic Melanoma or Renal Cell Cancer
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
Not specified
Sponsor:
NCI
Protocol IDs:
NCI-98-C-0040
, NCI-T97-0092, T97-0092, NCT00019396
15.
Phase II Study of Vaccination with Synthetic Melanoma Peptide Administered with Sargramostin (GM-CSF) Plus Interleukin-2 in Patients with Advanced Melanoma (Summary Last Modified 04/2002)
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18-79
Sponsor:
NCI
Protocol IDs:
UVACC-HIC-7621
, UVA-HIC-7621, NCI-G98-1389, NCT00003222
16.
Phase II Randomized Study of Vaccine Comprising Tyrosinase Peptide and gp100 Antigen With Montanide ISA-51 Alone or With Sargramostim (GM-CSF) in Patients with Resectable Stage IIA or IIB Melanoma (Summary Last Modified 11/2001)
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
LAC-USC-10M971
, LAC-USC-FDR001101, NCI-T97-0100, NCT00003274, T97-0100
17.
Phase II Study of Cloned Peripheral Blood Lymphocytes Sensitized In Vitro to the gp209-2M Immunodominant Peptide Alone or in Conjunction With Interleukin-2 in Patients With Metastatic Melanoma Who Have Failed Prior Vaccine Therapy
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-98-C-0095
, NCI-T98-0012, T98-0012, NCT00019487
18.
Phase II Randomized Study of a Vaccine Combining Tyrosinase and gp100 Peptides Emulsified with Montanide ISA-51 With or Without Interleukin-12 for Patients with Resected Stage III or IV Melanoma (Summary Last Modified 03/2000)
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
LAC-USC-10M973
, NCI-G98-1432, NCI-T97-0099, NCT00003339, T97-0099
19.
Phase II Randomized Study of gp100-Tyrosinase Peptide Vaccine Using Sargramostim (GM-CSF), Montanide ISA-51, or QS21 as Adjuvant in Patients with Advanced Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MSKCC-98012
, NCI-T97-0110, NCT00003362, T97-0110
20.
Phase II Study of Immunization With gp100 Antigen With Endoplasmic Reticulum Insertion Signal Sequence Alone or in Combination With Interleukin-2 in Patients With Metastatic Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-98-C-0142
, NCI-T98-0036, T98-0036
21.
Phase II Randomized Pilot Study of Vaccine Therapy With Tumor-Specific Mutated von Hippel-Lindau Peptides in Patients With Renal Cell Carcinoma
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-98-C-0139
, NCI-T97-0081, T97-0081, NCT00019526
22.
Phase II Randomized Study of Mutated gp100 Melanoma Peptide With High-Dose Interleukin-2 in HLA-A2.1-Positive Patients With Metastatic Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
CWG-UIC-T98-0027
, NCI-T98-0027, NCT00003568, T98-0027
23.
Phase II Study of MART-1 and gp100 Peptides Modified to Increase Binding to HLA-A0201 With or Without Interleukin-2 in Patients With Metastatic Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
NCI-99-C-0092
, NCI-T99-0033, T99-0033, NCT00019721
24.
Phase II Randomized Study of Mutated gp100 Melanoma Vaccine in HLA-A2-Positive Patients With at Least 1 mm Melanoma on Initial Biopsy
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
Over 16
Sponsor:
NCI
Protocol IDs:
PPMC-IRB-99-9
, NCI-T98-0081, NCT00003895, T98-0081
25.
Phase II Study of Immunization Using gp100:44-59, gp100:209-217 (210M), and MART-1:26-35 (27L) Antigen Peptides in HLA-DRB1*0401 Positive Patients With Metastatic Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
NCI-99-C-0159
, NCI-T99-0079, T99-0079, NCT00019994
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute